Entry |
|
Name |
Efalizumab (USAN/INN); Raptiva (TN) |
Remark |
|
Efficacy |
Antipsoriatic, Immunosuppressant, Anti-CD11a antibody |
Type |
Monoclonal antibody |
Comment |
Treatment of transplant rejections
|
Target |
|
Pathway |
hsa04650 | Natural killer cell mediated cytotoxicity |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG02 Efalizumab
D03959 Efalizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGAL (CD11A)
D03959 Efalizumab (USAN/INN)
|
Other DBs |
|
LinkDB |
|